Astellas Pharma highlights PHEN's "infotainment" initiative in its Change Together online portal
Androgen-deprivation therapy (ADT) with docetaxel may improve quality of life (QoL) at 12 months among patients with metastatic hormone-sensitive prostate cancer
Treatment with Xtandi (enzalutamide) reduced the risk of metastasis or death in castration-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate.
African American participation in prostate cancer clinical trials must move from 3-5% range to 10-12% range to determine the effectiveness of new treatments.
Clinical trials have found that Enzalutamide and Apalutamide are both able to significantly delay prostate cancer progression in men with non-metastatic castration-resistant prostate cancer.
During a regular check-up in 2008, Ray Fuller was diagnosed with prostate cancer. There was no family history of the disease, he said, it “just popped up.”
New research demonstrates how the fat contained within the Western diet, in combination with genetic factors, can cause prostate cancer tumors to spread.